Week in Review: Hutchison China MediTech (Chi-Med) Forms Drug Development JV With Nestle SA  
12/3/2012 1:17:40 PM

by Richard Daverman, PhD

December 1, 2012 -- Hutchison Chi-Med and Nestlé formed a JV based on Chi-Med’s expertise in TCM, including Hutchison’s drug candidate for ulcerative colitis and Crohn’s disease; Crown Bioscience will join with Beijing Purunao Biotech to develop small molecule drugs aimed at oncology targets; Fosun Pharma and the Shanghai Institute of Materia Medica will jointly develop an innovative oncology drug; a 24% stake in China Pharmaceutical R&D Center Co. is up for sale at a price of $2.5 million; ChinaBio® recently completed a survey of 70 participants in the China healthcare sector, finding that they have grown more optimistic over the past year; AstraZeneca was given SFDA approval for Brilinta, a drug that fights blood clots, Qiagen won SFDA approval for its careHPV Test, an HPV test for remote areas; and TTY Biopharm, a Taiwanese drugmaker, opened its new $100 million drug manufacturing facility in Suzhou. More details….

Stock Symbols: (AIM: HCM) (SHA: 600196; HK: 2196) (NYSE: AZN) (NSDQ: QGEN)